1. LBA3 Compartmental radioimmunotherapy (cRIT) 131I-OMBURTAMAB in patients with neuroblastoma (NB) central nervous system (CNS) and/or leptomeningeal (LM) metastases: Updated results from pivotal Trial 101. (December 2022) Authors: Basu, E.; Mora, J.; Streby, K.; Bear, M.; Sano, H.; Marachelian, A.; Harrison, D.; Nysom, K.; Pandit-Taskar, N.; Zanzonico, P.; Fabricius, S.; During, M.; Nielsen, J.R.; Kramer, K. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗